These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 32102735)

  • 1. A phase II study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with malignant pleural mesothelioma.
    Zucali PA; Perrino M; De Vincenzo F; Giordano L; Cordua N; D'Antonio F; Santoro A
    Lung Cancer; 2020 Apr; 142():132-137. PubMed ID: 32102735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma.
    Tsao AS; Harun N; Lee JJ; Heymach J; Pisters K; Hong WK; Fujimoto J; Wistuba I
    Clin Lung Cancer; 2014 May; 15(3):197-201. PubMed ID: 24492162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy.
    Toyokawa G; Takenoyama M; Hirai F; Toyozawa R; Inamasu E; Kojo M; Morodomi Y; Shiraishi Y; Takenaka T; Yamaguchi M; Shimokawa M; Seto T; Ichinose Y
    Int J Clin Oncol; 2014 Aug; 19(4):601-6. PubMed ID: 24158772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Irinotecan and Gemcitabine as Second-Line Treatment in Patients with Malignant Pleural Mesothelioma following Platinum plus Pemetrexed Chemotherapy: A Retrospective Study.
    Koda Y; Kuribayashi K; Doi H; Kitajima K; Nakajima Y; Ishigaki H; Nakamura A; Minami T; Takahashi R; Yokoi T; Kijima T
    Oncology; 2021; 99(3):161-168. PubMed ID: 33053560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.
    Zucali PA; Ceresoli GL; Garassino I; De Vincenzo F; Cavina R; Campagnoli E; Cappuzzo F; Salamina S; Soto Parra HJ; Santoro A
    Cancer; 2008 Apr; 112(7):1555-61. PubMed ID: 18286536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of First-Line Chemotherapeutics and Validation of the EORTC Prognostic Index in Malignant Pleural Mesothelioma: Retrospective Single-Centre Experience.
    Sezgin Y; Karhan O; Ileri S; Ebinc S; Tunc S; Urakci Z
    J Coll Physicians Surg Pak; 2024 Aug; 34(8):904-909. PubMed ID: 39113507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: a mono-institutional experience.
    Pasello G; Nicotra S; Marulli G; Rea F; Bonanno L; Carli P; Magro C; Jirillo A; Favaretto A
    Lung Cancer; 2011 Sep; 73(3):351-5. PubMed ID: 21296448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901.
    Dudek AZ; Wang X; Gu L; Duong S; Stinchcombe TE; Kratzke R; Borghaei H; Vokes EE; Kindler HL
    Clin Lung Cancer; 2020 Nov; 21(6):553-561.e1. PubMed ID: 32727707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Predictive Value of ERCC1, RRM1, and Thymidylate Synthase in Advanced Malignant Pleural Mesothelioma Patients Treated with Platinum-Based Chemotherapy.
    Wahba NI; Khorshid O; Abo Elkasem F; Bahnassy A; Gaafer R
    Asian Pac J Cancer Prev; 2023 Jan; 24(1):195-205. PubMed ID: 36708568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.
    Zucali PA; Perrino M; Lorenzi E; Ceresoli GL; De Vincenzo F; Simonelli M; Gianoncelli L; De Sanctis R; Giordano L; Santoro A
    Lung Cancer; 2014 Jun; 84(3):265-70. PubMed ID: 24321581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Third-line chemotherapy with carboplatin, gemcitabine and liposomised doxorubicin for malignant pleural mesothelioma.
    de Lima VA; Sørensen JB
    Med Oncol; 2015 Feb; 32(2):458. PubMed ID: 25572813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma.
    Miyamoto Y; Kozuki T; Aoe K; Wada S; Harada D; Yoshida M; Sakurai J; Hotta K; Fujimoto N
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34711664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.
    Hassan R; Kindler HL; Jahan T; Bazhenova L; Reck M; Thomas A; Pastan I; Parno J; O'Shannessy DJ; Fatato P; Maltzman JD; Wallin BA
    Clin Cancer Res; 2014 Dec; 20(23):5927-36. PubMed ID: 25231400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients.
    Shukuya T; Takahashi T; Imai H; Tokito T; Ono A; Akamatsu H; Taira T; Kenmotsu H; Naito T; Murakami H; Endo M; Yamamoto N
    Respir Investig; 2014 Mar; 52(2):101-6. PubMed ID: 24636265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Pinto C; Zucali PA; Pagano M; Grosso F; Pasello G; Garassino MC; Tiseo M; Soto Parra H; Grossi F; Cappuzzo F; de Marinis F; Pedrazzoli P; Bonomi M; Gianoncelli L; Perrino M; Santoro A; Zanelli F; Bonelli C; Maconi A; Frega S; Gervasi E; Boni L; Ceresoli GL
    Lancet Oncol; 2021 Oct; 22(10):1438-1447. PubMed ID: 34499874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effectiveness and safety of platinum-based pemetrexed and platinum-based gemcitabine treatment in patients with malignant pleural mesothelioma.
    Ak G; Metintas S; Akarsu M; Metintas M
    BMC Cancer; 2015 Jul; 15():510. PubMed ID: 26156324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study.
    Nakano T; Kuribayashi K; Kondo M; Morise M; Tada Y; Hirano K; Hayashi M; Tanaka M; Hirabayashi M
    Asia Pac J Clin Oncol; 2021 Jun; 17(3):264-272. PubMed ID: 32893992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma.
    Jänne PA; Simon GR; Langer CJ; Taub RN; Dowlati A; Fidias P; Monberg M; Obasaju C; Kindler H
    J Clin Oncol; 2008 Mar; 26(9):1465-71. PubMed ID: 18349397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RRM1 and ERCC1 as biomarkers in patients with locally advanced and metastatic malignant pleural mesothelioma treated with continuous infusion of low-dose gemcitabine plus cisplatin.
    Muñoz-Montaño W; Muñiz-Hernández S; Avilés-Salas A; Catalán R; Lara-Mejía L; Samtani-Bassarmal S; Cardona AF; Mendoza-Desión J; Hernández-Cueto D; Maldonado A; Baay-Guzmán G; Huerta-Yepes S; Arrieta O
    BMC Cancer; 2021 Aug; 21(1):892. PubMed ID: 34353292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Analysis of the Efficacy of Pemetrexed Maintenance Therapy in Patients with 
Malignant Pleural Mesothelioma].
    Zeng X; Jiang Z; Duan J
    Zhongguo Fei Ai Za Zhi; 2022 Jan; 25(1):7-13. PubMed ID: 35078279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.